Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19155007 | 0.90 | CHRNB2 (0.45) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| Tert-Butyl Formate SCHEMBL28128252 | 0.90 | RBP4 (0.39) | CHRNB2CHRNA4TLR2SLC6A2SLC6A4 | |
| SCHEMBL20847743 | 0.81 | HTR2C (0.39) | CHRNB2CHRNA4TLR2SLC6A2SLC6A4 | |
| SCHEMBL13646074 | 0.81 | HTR2C (0.47) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17397635 | 0.81 | RBP4 (0.48) | CHRNB2CHRNA4ALDH1A1KDM4ELMNA | |
| SCHEMBL13645914 | 0.80 | CHRNB2 (0.44) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1763854 | 0.79 | RBP4 (0.55) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17397765 | 0.79 | RBP4 (0.47) | ALDH1A1KDM4ELMNARBP4MEN1 | |
| Hydrochloric Acid SCHEMBL3861904 | 0.78 | CHRNB2 (0.43) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7818115 | 0.78 | CHRNB2 (0.44) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3164395-B1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| EP-3164395-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Novartis AG (CH) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001875-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | CHRNB2 451/4885CHRNA4 790/4885TLR2 3202/4885 |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | CHRNB2 451/4885CHRNA4 790/4885TLR2 3202/4885 |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | CHRNB2 451/4885CHRNA4 790/4885TLR2 3202/4885 |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | CHRNB2 451/4885CHRNA4 790/4885TLR2 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.